SAN DIEGO, Nov. 3 /PRNewswire-FirstCall/ -- MicroIslet Inc. announced that its President and COO Haro Hartounian, Ph.D. will speak at the Rodman & Renshaw 7th Annual Techvest Healthcare Conference on Tuesday, November 8th at 3:30 PM (EST) in the Holmes II Room at the New York Palace Hotel in New York City. MicroIslet is one of over 290 invited companies to present at this conference, to be held November 7-9, 2005.
MicroIslet is not only seeking to free millions of insulin-dependent diabetics from daily injections in the near term, but potentially to offer them a curative treatment in the long term. In his presentation at the conference, Dr. Hartounian will present the Company’s innovative strategy for using microencapsulated porcine islets to treat insulin-dependent diabetes and its potential to reduce the staggering $132 billion that the CDC estimates is spent each year on diabetes-related healthcare. Highlights will include the Company’s stellar roster of Scientific Advisory Board members, its strategic partnerships, including a unique islet supply partnership with the Mayo Clinic, and the potential impact of the recently enacted Pancreatic Islet Cell Transplant Act.
A live webcast of the presentation can be accessed by following the link for MicroIslet on the “Conference Webcasting” page under “Upcoming Conferences” at www.rodmanandrenshaw.com, URL http://wsw.com/webcast/rrshq7/mii/, or through the investor relations section of the Company’s website at www.microislet.com. Listeners are encouraged to visit the Web site at least 15 minutes prior to the beginning of the scheduled presentation to register and download and install any necessary audio software. The presentation will be archived on the same Web sites and available for a 90-day period.
About MicroIslet
MicroIslet is a biotechnology company engaged in the research, development, and commercialization of patented technologies in the field of transplantation therapy for people with insulin-dependent diabetes. MicroIslet’s patented islet transplantation technology, exclusively licensed from Duke University, includes methods for isolating, culturing, cryopreservation, and immuno-protection (microencapsulation) of islet cells. MicroIslet is working to develop and commercialize a first product, called MicroIslet-P(TM), a microencapsulated porcine islet cell suspension that will be used for transplantation in patients with insulin-dependent diabetes.
Except for the historical information contained herein, the matters set forth in this press release, including the anticipated benefits of data from The Scripps Research Institute in guiding primate studies of MicroIslet’s microencapsulated porcine islet cell suspension, the expectation of development of new therapeutic products, and the impact of MicroIslet’s products on diabetes patients, are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties inherent in medical treatment discovery, development and commercialization, the risks and uncertainties associated with MicroIslet’s early stage xenotransplantation technologies, the risks and uncertainties of governmental approvals and regulation, MicroIslet’s need to raise substantial additional capital to execute its business plan, the risks that MicroIslet’s competitors will develop or market technologies or products that are more effective or commercially attractive than MicroIslet’s products, and other risks detailed from time to time in MicroIslet’s most recent filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. MicroIslet disclaims any intent or obligation to update these forward-looking statements.
For more information, please visit our Web site at www.microislet.com.
For further information, please contact: Haro Hartounian, Ph.D., President and Chief Operating Officer of MicroIslet, Inc., +1-858-657-0287, info@microislet.com.
MicroIslet Inc.
CONTACT: Haro Hartounian, Ph.D., President and Chief Operating Officer ofMicroIslet, Inc., +1-858-657-0287, info@microislet.com
